Physician profile
Paul Schulman
NPI 1639165541
$54,248.92
in general payments reported to CMS, 2019-2025
36 companies · $3,821 in 2025
The $3,821 reported for 2025 was more than what 82% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $19K · 2021: $6,815 · 2022: $4,304 · 2023: $5,877 · 2024: $3,557 · 2025: $3,821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $1,400 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,749.63 |
| Consulting Fee | $1,400.00 |
| Education | $104.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Rheumatology | $29,231.60 | 2019-2021 | |
| Abbvie INC. | $5,026.54 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $4,132.56 | 2019-2025 | Tavneos, Evenity, Enbrel |
| Janssen Biotech, INC. | $2,352.60 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Pfizer INC. | $2,002.30 | 2019-2025 | |
| Fresenius Kabi USA, LLC | $1,425.55 | 2023-2025 | Idacio |
| Ucb, INC. | $1,385.01 | 2019-2025 | Cimzia, Bimzelx |
| Lilly USA, LLC | $1,336.77 | 2019-2024 | Taltz, Zepbound |
| Horizon Therapeutics Plc | $862.66 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $822.56 | 2019-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $670.45 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $633.43 | 2021-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $610.78 | 2022-2025 | Ofev, Cyltezo |
| Radius Health, INC. | $495.03 | 2019-2025 | Tymlos |
| Fidia Pharma USA INC. | $494.91 | 2021-2025 | Hym/Hyn, Hymhyn |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Schulman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.